Left: UMAP projections of CD8⁺/WPRE⁺ (adoptive T cells) and CD8⁺/WPRE⁻ (endogenous T cells) cells mapped onto a reference TIL atlas reveal a reduced prevalence of exhausted CD8⁺ T cells and enrichment ...
A multi-institutional study led by researchers at UNC Lineberger Comprehensive Cancer Center, the Salk Institute for Biological Studies, and UC San Diego has uncovered new genetic rules that determine ...
Cancer's ability to evade immune destruction often hinges on a stealthy process—CD8⁺ T cell exhaustion. In this state, the immune system's most potent cancer killers lose their punch, silenced by ...
Despite improvements in therapies, multiple myeloma (MM) is a disease that will always relapse. Why is this? What is the key to finding effective therapies to cure MM? Evan Newell, a Professor in the ...
In a study published recently in Cancer Immunology, Immunotherapy journal, researchers from Jiangsu Province Hospital and colleagues investigated the impact of targeting the TP53-induced glycolysis ...
A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...
Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...
In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results